These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34984740)

  • 41. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
    Ewer MS; Glück S
    Cancer; 2009 May; 115(9):1813-26. PubMed ID: 19235248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
    Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
    J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients.
    Morales L; Timmerman D; Neven P; Paridaens R
    Int J Gynecol Cancer; 2006; 16 Suppl 2():515-7. PubMed ID: 17010061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
    Gandhi S; Verma S
    Breast Cancer Res Treat; 2007 Nov; 106(1):1-9. PubMed ID: 17211535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
    Akyol M; Alacacioglu A; Demir L; Kucukzeybek Y; Yildiz Y; Gumus Z; Kara M; Salman T; Varol U; Taskaynatan H; Oflazoglu U; Bayoglu V; Tarhan MO
    Cancer Biomark; 2017; 18(4):441-449. PubMed ID: 28106545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN
    Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association Between Aromatase Inhibitors and Myocardial Infarction Morbidity in Women With Breast Cancer: A Meta-Analysis of Observational Studies.
    Sun JC; Sun ZF; He CJ; Zhai CL; Qian G
    Cancer Control; 2022; 29():10732748221132512. PubMed ID: 36346929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
    Nabholtz JM; Gligorov J
    Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.
    Foglietta J; Inno A; de Iuliis F; Sini V; Duranti S; Turazza M; Tarantini L; Gori S
    Clin Breast Cancer; 2017 Feb; 17(1):11-17. PubMed ID: 27561703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea.
    Kim JE; Choi J; Park J; Han W; Kang D; Choi JY
    J Am Heart Assoc; 2022 Oct; 11(20):e026743. PubMed ID: 36250658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microvascular breast reconstruction and thromboembolic events in patients on hormone therapy: Audit of practice from a tertiary referral centre.
    Samaras S; Ashfield S; Ali SF; Fopp LJ; Benson JR; Malata CM
    J Plast Reconstr Aesthet Surg; 2021 May; 74(5):957-965. PubMed ID: 33221183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
    Karaboyun K; Cavdar E; Irıagac Y; Celebı A; Kapagan T; Gulturk I; Demır O; Avcı O; Seber ES
    Support Care Cancer; 2023 May; 31(6):330. PubMed ID: 37162602
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.